Floatz logo

ETOPOSIDE

Oral

Peking University People's HospitalSmall moleculeN/AActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

7 Active assets in the Oral cohort.

Asset / SponsorPhaseRating
Datopotamab Deruxtecan
AstraZeneca
Phase 4BB
Methylene Blue
Mayo Clinic
Phase 3BB
DEXAMETHASONE
AstraZeneca
Phase 4BB
Palifermin
Swedish Orphan Biovitrum
Phase 3B
MECLOCYCLINE SULFOSALICYLATE
Mucosal Therapeutics
Phase 2B

View all 17 →

Same molecule, other indications

ETOPOSIDE is also rated in:

acute megakaryoblastic leukemiaDormant
BBB
Indicative ·
79 / 100
View asset →
acute monocytic leukemiaDormant
BBB
Indicative ·
79 / 100
View asset →
acute myeloblastic leukemia with maturationDormant
BBB
Indicative ·
79 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →